Fortrans

Pharmacological properties

due to the formation of hydrogen bonds with water molecules, fortrans holds it in the intestine. water fills and increases the contents of the intestine along its entire length. after this, the drug is completely evacuated from the intestine along with its contents.

The volume of non-adsorbed fluid in the intestine is responsible for the laxative effect of the drug solution.

Pharmacokinetics The drug is not absorbed or metabolized. It is excreted unchanged from the body.

Indications

Bowel cleansing to prepare patients for endoscopic and radiological examinations, intestinal surgery.

Application

Fortrans is used only in adult patients. for oral use.

Dissolve the contents of each bag in 1 liter of water until the powder is completely dissolved.

The dose is set at the rate of approximately 1 liter of solution per 15-20 kg of body weight. The dose is 3-4 liters of solution, depending on the patient’s body weight.

The drug can be used in 1 or 2 stages, provided that the reconstituted solution is taken completely (an average of 3-4 liters of solution, depending on the patient’s body weight).

Preparation scheme

One-stage preparation: 3-4 liters in the evening before the procedure, a break of 1 hour after the first 2 liters is possible.

Two-stage preparation: 2 liters in the evening before the procedure and 1-2 liters in the morning on the day of the procedure, take the last glass 3-4 hours before the procedure, or 3 liters in the evening before the procedure and 1 liter in the morning on the day of the procedure, take the last glass for 3-4 hours before the procedure.

The recommended rate of use of the drug is 1-1.5 l / h (250 ml every 10-15 minutes).

The doctor can individually determine the recommended rate of use of the drug according to the clinical condition of the patient and potential concomitant diseases.

Patients with impaired renal function. There are insufficient data for this category of patients (see SPECIAL INSTRUCTIONS).

Children. The safety and effectiveness of the drug Fortrans for children (under the age of 18 years) has not been established.

Contraindications

• Hypersensitivity to the active or excipients of the drug; severe disturbances in the general condition of the patient, for example, dehydration or severe heart failure; widespread carcinoma or any other disease of the large intestine, accompanied by widespread damage to the intestinal mucosa; the presence or risk of intestinal obstruction or gastrointestinal obstruction; perforation or threat of perforation of the gastrointestinal tract; abdominal pain of uncertain origin; gastric emptying disorders (e.g. gastroparesis); toxic colitis or toxic megacolon.

Side effects

Diarrhea is an expected consequence of the use of the drug Fortrans.

At the beginning of the administration, attacks of nausea and vomiting were noted, which usually disappeared with further use.

The following are adverse reactions from clinical trials and adverse events reported during post-registration studies. The frequency is defined as follows: very often (≥1 / 10), often (≥1 / 100 to 1/10), infrequently (≥1 / 1000 to 1/100), rarely (≥1 / 10,000 to 1/1000) , very rarely (1/10 000), unknown (cannot be estimated based on available data).

From the digestive system: very often - nausea, abdominal pain, bloating; often vomiting.

On the part of the immune system: unknown - hypersensitivity reactions, including anaphylactic shock, angioedema, urticaria, rash, itching.

special instructions

Elderly people with poor health are recommended to use the drug only under the supervision of a doctor.

Diarrhea caused by the use of the Fortrans drug may interfere with the absorption of drugs taken concurrently with this drug (see INTERACTIONS).

This medicine contains polyethylene glycol (PEG).

Allergic reactions that have been reported with the use of drugs based on macrogol: anaphylactic shock, rash, urticaria, angioedema (see ADVERSE EFFECTS).

The drug should not cause disturbances in the electrolyte balance, taking into account its isotonic composition; however, exceptional cases of water-electrolyte disturbances were recorded in patients at risk. Patients with manifestations of dehydration or persons with electrolyte disorders should be eliminated before using the drug to cleanse the intestines. This medicine should be used with caution in patients with such disorders, as well as those who are simultaneously taking drugs that increase the risk of water-electrolyte disorders, including hyponatremia and hypokalemia, or the risk of potential complications (for example, patients with impaired renal function, heart failure or with simultaneous treatment with diuretic drugs). In this case, patients need proper supervision.

Patients prone to aspiration, bedridden, or with neurological and / or motor impairment due to the risk of developing aspiration pneumonia, it is recommended to use the drug with caution and only under medical supervision. Such patients should administer the drug in a sitting position and through a nasogastric tube.

Patients with heart or kidney failure may develop acute pulmonary edema due to excess water intake.

This medicine contains sodium. The drug contains 1.967 g of sodium per 1 sachet. This should be considered in patients on a salt-restricted diet.

Use during pregnancy and lactation

Pregnancy. Data on the use of the drug Fortrans in pregnant women are absent or limited. Data from preclinical studies on reproductive toxicity are insufficient.

Fortrans can be used only after a thorough assessment of the risk ratio for the fetus and the benefits for the mother.

Lactation. Data on the use of the drug Fortrans during lactation are absent or limited. It is not known whether Macrogol 4000 is excreted in breast milk. The risk to newborns / infants cannot be ruled out.

Fortrans can be used only after a thorough assessment of the risk ratio for the fetus and the benefits for the mother.

Fertility. There is no evidence of the effect of Fortrans on fertility.

If a woman is pregnant or breastfeeding, or if pregnancy is suspected or planned, you should consult your doctor before using Fortrans

Children. Do not use in children.

The ability to influence the reaction rate when driving vehicles or working with other mechanisms. Studies of the impact on the ability to drive vehicles and work with mechanisms have not been conducted.

Interactions

The healthcare provider who prescribes the treatment should be informed of any other medicines that the patient is taking orally at the same time. due to the emptying of the stomach caused by fortrans, other drugs for oral administration may not be absorbed, so they should be taken no later than 2 hours before taking the solution. it is necessary to avoid taking medications for oral use before and after taking a laxative until the medical examination is completed. for drugs with a narrow therapeutic range or short t½, a particular effect on effectiveness is possible.

Overdose

No overdose reports received.

However, you should monitor the water-electrolyte balance and the level of hydration in the patient in case of overdose with severe diarrhea.

Storage conditions

It does not require special storage conditions. Keep out of the reach of children.